Smith D J, Taubman M A
Department of Immunology, Forsyth Dental Center, Boston, Massachusetts 02115.
Infect Immun. 1987 Nov;55(11):2562-9. doi: 10.1128/iai.55.11.2562-2569.1987.
The effect of oral administration of glucosyltransferase (GTF) from Streptococcus sobrinus 6715 on levels of immunoglobulin A (IgA) antibody to GTF in parotid saliva and on the number of indigenous Streptococcus mutans in the whole saliva was studied in young adult males. GTF combined with aluminum phosphate (AP) was administered in capsules to 14 subjects, while sodium phosphate buffer combined with AP was administered in the same way to 11 control subjects. Thirteen administrations were given during the first immunization regimen, and five administrations, approximately 3 months later, constituted the second immunization regimen. All subjects were given professional dental prophylaxis immediately prior to each immunization. Each subject served as his own control by using antibody and bacterial data collected prior to antigen administration for comparison. After the first immunization regimen, the GTF vaccine group exhibited a significantly higher distribution (P less than 0.05) of normalized parotid saliva IgA antibody elevations than observed in the placebo group. Between the first and second immunization regimens a significant increase (P less than 0.05) in parotid salivary anti-GTF activity also occurred in the GTF vaccine but not the placebo group. No significant differences between these two groups were observed on any occasion when serum IgG or IgA antibody to GTF was analyzed. Comparison of the group mean log ratios (post- to prevaccine administration) of S. mutans to total streptococci in whole saliva revealed that the GTF vaccine group values were always lower than those of the placebo group. These differences reached significance (P less than 0.01) on three of the last four sampling occasions (days 21, 35, and 42) following initiation of the first immunization regimen. The mean log ratios of the GTF vaccine group were also lower than those of the placebo group after the second immunization regimen but did not reach significance. These data indicate that oral administration of GTF from the mutans streptococci has the potential to elicit a salivary IgA antibody response when combined with an aluminum-based adjuvant and that this response can interfere with the reaccumulation of indigenous S. mutans following dental prophylaxis.
在年轻成年男性中,研究了口服来自远缘链球菌6715的葡糖基转移酶(GTF)对腮腺唾液中GTF免疫球蛋白A(IgA)抗体水平以及全唾液中本土变形链球菌数量的影响。将GTF与磷酸铝(AP)混合制成胶囊,给予14名受试者,同时以相同方式将磷酸钠缓冲液与AP给予11名对照受试者。在首次免疫方案期间给予13次给药,大约3个月后给予5次给药,构成第二次免疫方案。每次免疫前,所有受试者均接受专业的牙齿预防治疗。通过使用抗原给药前收集的抗体和细菌数据进行比较,每个受试者作为自身对照。首次免疫方案后,GTF疫苗组标准化腮腺唾液IgA抗体升高的分布显著高于安慰剂组(P小于0.05)。在首次和第二次免疫方案之间,GTF疫苗组腮腺唾液抗GTF活性也显著增加(P小于0.05),而安慰剂组未出现这种情况。在分析血清中GTF的IgG或IgA抗体时,这两组在任何情况下均未观察到显著差异。比较全唾液中变形链球菌与总链球菌的组平均对数比(疫苗给药后与给药前),发现GTF疫苗组的值始终低于安慰剂组。在首次免疫方案开始后的最后四次采样中的三次(第21、35和42天),这些差异具有统计学意义(P小于0.01)。第二次免疫方案后,GTF疫苗组的平均对数比也低于安慰剂组,但未达到统计学意义。这些数据表明,当与铝基佐剂联合使用时,口服变形链球菌的GTF有可能引发唾液IgA抗体反应,并且这种反应可以干扰牙齿预防治疗后本土变形链球菌的重新积累。